Sally Frautschy, Ph.D.

David Geffen School of Medicine at UCLA

Director, Sally A. Frautschy Alzheimer Research Laboratory

VA Greater Los Angeles Healthcare System
West Los Angeles Medical Center
11301 Wilshire Blvd., Building 114, Room #114
Los Angeles, CA 90073
Tel: (310) 478-3711 x46499
Email: sfrautschy@mednet.ucla.edu

Biography

Dr. Frautschy's focus in her graduate & initial post-graduate work was to understand the adverse effects of chronic stress on physiology, intrigued by the work of Hans Selye, who in 1956 coined the word "stress" from physics to use to describe the physiological/chemical response to an emotional reaction. She worked under experts in the field of 'stress', completing her MS under the late Gary Moberg at UC Davis in 1980 and Ph.D. in 1986 under Professor Robert Liptrap, DVM, Ph.D. at Univ. of Guelph, Ontario, Canada (also a photographer.) After completing her Ph.D., she trained with Dipak Sarkar (UCSD, now at Rutgers), another neuroendocrinologist. During her 2nd postdoc with Dr. Andrew Baird & directorship of Roger Guillemin (a Nobel laureate who did his postdoc under Hans Selye), Sally worked on brain injury induction of neurotrophic factors where she began her collaboration with Dr. Cole. Many neurotrophic factors become elevated in the Alzheimer's brain as a 'response' to injury. In 1988, Dr. Frautschy, in collaboration with Dr. Cole, decided to evaluate the brain's response to human amyloid and was the first to describe the inflammatory response. Since then, her priority has been to develop practical and effective approaches, particularly nutritional, for stopping this tragic disease, which in part, evolves from a personal experience with a head injury.

Specialty

Alzheimer's Disease.

Affiliations

COMPLETED - Project 3: Efficacy of New Drugs Directed against Beta Amyloid using in vitro and in vivo Models

Sally A. Frautschy Alzheimer Research Laboratory

Publications

Ma QL, Yang F, Frautschy SA., Cole GMPAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell Logist 2012;2(2):117-125. PMID: 23162743; PMCID: PMC3490962

Ma QL, Zuo X, Yang F, Ubeda O, Gant D, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA. Curcumin suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice. J Biol Chem 2012 Dec 21. PMID: 23264626

Roychaudhuri R, Yang M, Deshpande A, Cole GM, Frautschy S, Lomakin A, Benedek GB, Teplow DB. C-Terminal Turn Stability Determines Assembly Differences between Aβ40 and Aβ42. J Mol Biol 2013;425(2):292-308. doi: 10.1016/j.jmb.2012.11.006. PMID: 23154165

Frautschy SA, Cole GM. What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimers Res Ther 2011 Jan 20;3(1):2. doi: 10.1186/alzrt61. PMID: 21251328; PMCID: PMC3109411

Cole GM, Frautschy SA. Why pleiotropic interventions are Needed for Alzheimer's disease. Mol Neurobiol. 2010 Jun;41(2-3):392-409.

Cole GM, Frautschy SA. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):140-148.

Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010;140(4):869-874.

Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLa/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer Disease Cerebrospinal Fluid.  Arch Neurol 2009 Apr;66(4):448-457.

Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009 Feb;33(2):193-206.

Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA. Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis 2008 Dec;15(4):625-640.

Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull K, Teter B, Cole GM, Frautschy SA. Curcumin structure-function, bioavailablity and efficacy in models of neuroinflammation and Alzheimer’s.  J Pharmacol Exp Ther 2008 Jul;326(1):196-208.

Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM.  P21-activated kinase aberrant activation and translocation in Alzheimer's disease pathogenesis. rrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem 2008 May 16;283(20):14132-14143.

Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, Cole GM.  Omega-3 Fatty Acid Docosahexaenoic Acid Increases Sorla/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer Disease (AD): Relevance to AD Prevention.  Journal of Neuroscience December 26, 2007;27(52):14299 –14307.